Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotechnology company in clinical phase that is developing the drug candidate arfolitixorin that aims to increase the efficacy of standard treatments for patients with severe forms of cancer.
Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s shares are traded on Nasdaq Stockholm.
Latest press releases
2026-08-25
Interim report Q2 2026
”The second quarter of 2026 was characterized by a continued strong focus on advancing the clinical development of our drug candidate arfolitixorin toward becoming a new cornerstone of cancer treatment. During the quarter, we placed additional emphasis on optimizing the study design and accelerating patient recruitment. With a newly opened investigational site in Germany in the third quarter and approval from the Safety Review Committee to initiate the highest dose-escalation cohort of 500 mg/m2, we are shifting into a higher gear as we advance toward the phase II part of the study.” says CEO, Petter Segelman Lindqvist.
2026-05-21
ABGSC Investor Days
Isofol participated in ABGSC Investor Days and CEO, Petter Segelman Lindqvist, provided an update on the company and the ongoing clinical phase Ib/II study.
2026-05-19
Interim report Q1 2026
”We look forward to continuing to advance the clinical development of arfolitixorin with a strengthened cash position and the new regulatory approvals in place,” says CEO, Petter Segelman Lindqvist.
For investors
Upcoming Events
- November 12, 2026 - November 12, 2026
Interim report July-September 2026
Latest reports and presentations
